IPO or Sale? Why Life Sciences Companies Don’t Have to Choose
For late-stage private life sciences companies contemplating their exit strategy, the choice between an IPO and a strategic sale may give way to a different question: Why choose at all? Taking a dual-track approach, in which a company prepares for a public offering and runs a private M&A process simultaneously, has long been an effective tool available to life sciences boards and management teams, and it’s just as applicable in today’s complex exit landscape.
If structured and executed thoughtfully, the dual-track approach may do more than hedge between two outcomes. It can create a dynamic in which each path strengthens the other: IPO readiness benchmarks standalone value and motivates potential acquirers to act, while M&A discussions provide real-time market intelligence about strategic interest and valuation. This leads to the possibility of a better-informed board, a more competitive process, and a higher-quality outcome on whichever path is ultimately pursued.
This alert lays out considerations for life sciences companies thinking of taking a dual-track approach.
Defining the Dual-Track Process: Running an IPO and a Strategic Sale Simultaneously
A dual-track process involves preparing for an IPO at the same time as running a private M&A process. The two processes share some overlapping workstreams, which makes the combined effort more manageable than it might appear, but each track also has its own distinct requirements, timeline, and audience.
Key characteristics of a dual-track process include:
- Parallel Preparation: Both tracks advance simultaneously, rather than sequentially. IPO and M&A workstreams share common elements, including financial models, diligence data rooms, and equity narratives, while maintaining separate processes and potentially separate advisory relationships.
- Genuine Optionality: The company retains the ability to pivot to either outcome based on market conditions, buyer interest, and the board’s judgment, without having foreclosed either path through prior commitments.
- Competitive Tension: Potential acquirers know the company has a viable standalone path and a clear timeline for a market value inflection point, giving the company the ability to increase the competitiveness of the process and accelerate timelines.
- Informed Decision-Making: By running both processes simultaneously, the board gains real-time visibility into public market valuations and strategic acquirer interest, enabling a more fully informed exit decision.
Why Life Sciences Companies Are Uniquely Positioned to Benefit from the Dual-Track Approach
The dual-track model is particularly well-suited to life sciences companies for several interconnected reasons. Strategic acquirers and public market investors often value the same clinical-stage asset very differently. A large pharma buyer may assign a significant premium to a pipeline asset that fills a gap in its portfolio, while public investors will be heavily focused on current valuations of comparable traded companies. Running both processes simultaneously surfaces this divergence and may allow the board to make a data-driven decision about which market is offering superior value at a given moment.
Life sciences IPO windows also open and close quickly, driven by clinical data readouts, regulatory decisions, macroeconomic events, and sector sentiment. Companies prepared for only one path may not be able to pivot fast enough when conditions shift. There is also a meaningful structural advantage to being acquired before going public. Pre-IPO, management retains significant control over the negotiating process. Once a company is public, a majority of shareholders can drive a sale process in ways that diminish management’s influence, and buyers may hold back their best offers in expectation of a public auction. Partially due to this dynamic, buyers can often offer materially higher valuations when the seller has a credible near-term IPO alternative.
Conversely, the same events that can open an IPO window for a company (such as data readouts or regulatory decisions) can also catalyze acquiror interest.
Before You Begin: Key Questions Every Board and Management Team Should Answer
Before launching a dual-track process, companies should consider working through the following questions:
Is the IPO path genuinely credible? A dual-track process derives its leverage from having a viable IPO alternative. If the company does not have the financial infrastructure, insider support, and clinical narrative to support a real public offering, the M&A track may not benefit from the competitive tension the model is designed to create.
Do we have the right financial infrastructure? IPO preparation requires PCAOB-compliant audits of at least two fiscal years, an accelerated financial close cycle, and management and controls capable of supporting public company reporting. M&A diligence requires the same underlying financial robustness. If these foundations are not in place, both tracks will be impaired.
Are there investor rights that could complicate either track? Strategic corporate investors often negotiate rights, including pro rata rights, acquisition rights of notice, rights of first refusal or negotiation, and board observer rights, that may constrain the company’s ability to negotiate freely with acquirers or complicate IPO disclosure. Companies should consider identifying and addressing these before launching either process.
Have we identified and resolved material diligence risks? Both sophisticated acquirers and public market investors may scrutinize IP ownership and licensing, regulatory compliance, data privacy and cybersecurity, and commercial agreements for change-of-control provisions that could veto a transaction. Issues discovered mid-process may be significantly more damaging than issues addressed in advance.
Are our management team and board prepared for the demands of a dual-track process? Running simultaneous IPO and M&A workstreams places significant demands on executive time and organizational capacity. Companies should assess honestly whether management bandwidth is available to support both processes without losing focus on the business.
How early should we start? Both tracks require up to 12 to 18 months of foundational preparation from a standing start. Companies should consider starting the process even earlier than they think necessary to avoid potentially compromising the credibility and competitiveness of both paths.
Executing the Dual-Track: Shared Workstreams, Key Preparation Steps, and Practical Guidance
The mechanics of a dual-track process are demanding but manageable when approached systematically. One of the most important insights for teams managing a dual-track process is that, while each has its own distinct workstreams and requirements, certain preparation serves both tracks simultaneously. A well-organized diligence data room, built once and replicated as appropriate for each process, can support both processes with similar underlying documentation. Likewise, financial models can be built to support both processes in appropriate ways. Capitalizing on these shared workstreams may allow companies to manage the resource burden of running both tracks at the same time.
On the governance front, both tracks benefit from a board that is evolving toward public-company standards, with independent directors, functioning audit and compensation committees, and governance practices that are defensible to public investors and M&A counterparties alike. Companies should consider building out these structures before either process launches. Companies should also review and align management compensation arrangements across both outcomes, including upon a change of control, since misaligned incentives may create friction at critical decision points in either process.
Most life sciences companies will qualify as emerging growth companies (EGCs) under the JOBS Act, which permits confidential draft registration statement submission before public filing. This accommodation may be especially valuable in a dual-track context because it allows a company to receive Securities and Exchange Commission feedback and refine its disclosure without publicly committing to an IPO, preserving the option to pivot to a sale if a compelling offer materializes before the registration statement becomes public.
Finally, information sharing deserves deliberate attention. M&A discussions require sharing nonpublic information with potential acquirers under confidentiality agreements, while IPO preparation ultimately requires public disclosure of some of the same information. Similarly, if parties involved in the M&A process may potentially be purchasers in the IPO, careful data room and diligence management are needed to avoid such parties being tainted with nonpublic information and thus unable to buy in the IPO. Managing the interaction between these obligations requires a proactive strategy developed with legal counsel before either track is launched.
Key Takeaways: Building a Dual-Track Strategy That Delivers
For life sciences companies weighing an exit in 2026, the dual-track process offers a framework for maximizing value in a market where IPO windows are narrow and M&A activity is surging. Companies taking this approach should consider the following principles:
Start earlier than you think you need to. Both tracks require up to 12 to 18 months of foundational preparation spent building governance, audit, diligence, and investor relationship infrastructure.
Both tracks must be credible. A dual-track process that is perceived as a bluff may not generate the competitive tension that makes it valuable. Invest meaningfully in both paths.
Audit your investor agreements. Identify rights held by strategic or corporate investors that could create friction in either an IPO or a sale and consider addressing them proactively.
Build your diligence data room from a buyer’s perspective. Address IP, regulatory, data privacy, cybersecurity, and contract issues before they surface in a live process.
Use the EGC confidential submission process strategically. The ability to receive SEC feedback before going public gives dual-track companies meaningful flexibility to assess M&A interest before committing publicly to an IPO.
Capitalize on shared workstreams. Align your financial models and diligence documents to serve both processes. Efficiency can make a dual-track process manageable.
Stay close to market conditions. The relative attractiveness of the IPO and M&A tracks may shift as clinical data readouts, FDA decisions, macroeconomic conditions, and acquirer activity evolve. Consider building a decision framework that allows management and the board to act decisively when conditions favor one path.